See if a behavioral coaching plus at-home exercise can help older blood cancer survivors slow aging
Official title: Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
Run by University of Nebraska · NCT07292272 · Data updated 2026-11-12
Aimed at people 50 and older who have had a blood cancer, this trial tests whether combining coaching with a virtual exercise program can help slow aging and improve health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years and up |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | University of Nebraska Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Omaha, Nebraska) |
| Status | Recruiting |
| Started | April 9, 2026 |
| Main results expected | March 25, 2032 |
| Study ends | March 25, 2033 |
| Registry record updated | July 1, 2026 |
| Trial ID | NCT07292272 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 50 or older with a history of a hematological malignancy who are able to participate in a virtual exercise program and provide informed consent.
✕Probably not a fit
Patients undergoing certain intensive treatments or with conditions that preclude safe aerobic exercise may not benefit and could be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 2 randomized trial exploring how behavioral coaching paired with a virtual exercise platform affects aging-related and health outcomes in older survivors of hematological malignancies. Participants will be randomized to receive structured behavioral support and access to an online exercise program, with safety and adherence monitored throughout. The study seeks to determine the dose and duration of exercise that could influence biological aging in this population. Eligibility includes adults 50 years or older with a history of hematological cancer who can provide informed consent, while certain active treatments and medical conditions exclude participation. The trial is led by the University of Nebraska, conducted at UNMC, and does not list additional collaborators at this time.
Why it matters
Potential benefit: If successful, participants may experience improvements in physical health, vitality, and possibly slower aging-related changes.
How similar studies have gone: Prior research suggests exercise and behavioral interventions can improve health in cancer survivors, but this specific combination in older blood cancer survivors is an area of active investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥50 years 2. A history of hematological malignancy 3. Participants must be able to and willingly give informed consent Exclusion Criteria: 1. Patients receiving intensive induction or consolidation chemotherapy. Maintenance chemotherapy, or lower-intensity chemotherapy for an indolent hematological malignancy is allowed. 2. Neurodegenerative disease (e.g. Alzheimer's dementia), stroke, or uncontrolled psychotic disorders (e.g. schizophrenia or bipolar disorder) in the past 3 months if those disorders are considered significant enough to impair participation in the study. 3. Illnesses such as clinical evidence of decompensated heart failure, unstable angina, or orthopedic or neuromuscular disorders that could limit safe participation in aerobic exercise. 4. Cardiopulmonary exercise test results that preclude safe exercise (e.g., life-threatening arrhythmia, balance difficulties, peak VO2 \<10 ml/kg/min). 5. Estimated life expectancy of less than 6 months (that precludes assessment of study primary endpoint). 6. Self-reported pregnancy or the possibility of pregnancy. 7. Participants who do not plan to follow up at the participating center.
Where it's running
-
University of Nebraska Medical Center
Omaha, Nebraska, United States Recruiting
Study contacts
- Principal investigator: Vijaya Raj Bhatt, MBBS,MS — University of Nebraska
- Study coordinator: Taylor Johnson
- Email: taylora.johnson@unmc.edu
- Phone: 402-559-4596
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating the risk of blood cancers in firefighters
This study is testing if firefighters who have been exposed to harmful substances are at a higher risk for blood cancers and related conditions.
-
Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues
This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.
-
Using Mitoxantrone for Treating Venetoclax Resistant Acute Myeloid Leukemia
This study is testing if a combination of mitoxantrone, venetoclax, and azacitidine can help people with acute myeloid leukemia who haven't responded to previous treatments.
-
Cord blood transplant for children and young adults with blood cancers.
This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.
-
Voice monitoring for side effects during CAR T-cell therapy
This project will test whether twice-daily smartphone voice recordings and brief daily neurologic checks can spot early neurologic side effects in adults receiving FDA-approved CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma.
-
High-altitude stem cell and bone marrow transplant registry on the Qinghai-Tibet Plateau
This project will collect clinical data and blood/bone marrow samples from people having hematopoietic stem cell transplants on the Qinghai‑Tibet Plateau to see how high altitude affects transplant outcomes and recovery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.